Sale Of Australia's HeartWare To Thoratec Of U.S. Canceled
This article was originally published in PharmAsia News
Australia's HeartWare International, maker of medical devices, may not be sold soon after all. The U.S. Federal Trade Commission indicated it would challenge the purchase, leading Thoratec to cancel the deal. The firm's CEO said the board decided not to pursue a deal it figured would be protracted, costly and unpredictable. The FTC was concerned the merger of the two companies would lead to a monopoly of the market for left ventricular assist devices, which are used in patients with advanced heart failure. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.